4 Dobretsov M, Stimers JR. Neuronal function and alpha3 isoform of the Na/K-ATPase. *Front Biosci* 2005; **10:** 2373–96.

5 Dobretsov M, Hastings SL, Sims TJ, Stimers JR, Romanovsky D. Stretch receptor-associated expression of alpha 3 isoform of the Na+, K+-ATPase in rat peripheral nervous system. *Neuroscience* 2003; **116:** 1069–80.

6 Crambert G, Hasler U, Beggah AT, et al. Transport and pharmacological properties of nine different human Na, K-ATPase isozymes. *J Biol Chem* 2000; **275:** 1976–86.

7 Senatorov VV, Mooney D, Hu B. The electrogenic effects of Na(+)-K(+)-ATPase in rat auditory thalamus. *J Physiol* 1997; **502:** 375–85.

8 Vaillend C, Mason SE, Cuttle MF, Alger BE. Mechanisms of neuronal hyperexcitability caused by partial inhibition of Na+-K+-ATPases in the rat CA1 hippocampal region. *J Neurophysiol* 2002; **88:** 2963–78.

9 Shiina N, Yamaguchi K, Tokunaga M. RNG105 deficiency impairs the dendritic localization of mRNAs for Na+/K+ ATPase subunit isoforms and leads to the degeneration of neuronal networks. *J Neurosci* 2010; **30:** 12816–30.

10 Blom H, Rönnlund D, Scott L, et al. Spatial distribution of Na+-K+-ATPase in dendritic spines dissected by nanoscale superresolution STED microscopy. *BMC Neurosci* 2011; **12:** 16.

11 Rose CR, Konnerth A. NMDA receptor-mediated Na+ signals in spines and dendrites. *J Neurosci* 2001; **21:** 4207–14.

12 Reinhard L, Tidow H, Clausen MJ, Nissen P. Na^+,K^+-ATPase as a docking station: protein-protein complexes of the Na^+,K^+-ATPase. *Cell Mol Life Sci* 2013; **70:** 205–22.

13 Brashear A, DeLeon D, Bressman SB, Thyagarajan D, Farlow MR, Dobyns WB. Rapid-onset dystonia-parkinsonism in a second family. *Neurology* 1997; **48:** 1066–69.

14 Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia-parkinsonism. *Neurology* 1993; **43:** 2596–602.

15 Kramer PL, Mineta M, Klein C, et al. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. *Ann Neurol* 1999; **46:** 176–82.

16 Pittock SJ, Joyce C, O'Keane V, et al. Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred. *Neurology* 2000; **55:** 991–95.

17 Zaremba J, Mierzewska H, Lysiak Z, Kramer P, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13. *Mov Disord* 2004; **19:** 1506–10.

18 de Carvalho Aguiar P, Sweadner KJ, Penniston JT, et al. Mutations in the Na+/K+ -ATPase alpha3 gene *ATP1A3* are associated with rapid-onset dystonia parkinsonism. *Neuron* 2004; **43:** 169–75.

19 Brashear A, Dobyns WB, de Carvalho Aguiar P, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the *ATP1A3* gene. *Brain* 2007; **130:** 828–35.

20 McKeon A, Ozelius LJ, Hardiman O, Greenway MJ, Pittock SJ. Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-parkinsonism kindred. *Mov Disord* 2007; **22:** 1325–27.

21 Barbano RL, Hill DF, Snively BM, et al. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. *Parkinsonism Relat Disord* 2012; **18:** 737–41.

22 Lee JY, Gollamudi S, Ozelius LJ, Kim JY, Jeon BS. *ATP1A3* mutation in the first Asian case of rapid-onset dystonia-parkinsonism. *Mov Disord* 2007; **22:** 1808–09.

23 Zanotti-Fregonara P, Vidailhet M, Kas A, et al. [123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia-parkinsonism. *J Neurol Sci* 2008; **273:** 148–51.

24 Blanco-Arias P, Einholm AP, Mamsa H, et al. A C-terminal mutation of ATP1A3 underscores the crucial role of sodium affinity in the pathophysiology of rapid-onset dystonia-parkinsonism. *Hum Mol Genet* 2009; **18:** 2370–77.

25 Anselm IA, Sweadner KJ, Gollamudi S, Ozelius LJ, Darras BT. Rapid-onset dystonia-parkinsonism in a child with a novel *ATP1A3* gene mutation. *Neurology* 2009; **73:** 400–01.

26 Svetel M, Ozelius LJ, Buckley A, et al. Rapid-onset dystonia-parkinsonism: case report. *J Neurol* 2010; **257:** 472–74.

27 Kamm C, Fogel W, Wächter T, et al. Novel *ATP1A3* mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. *Neurology* 2008; **70:** 1501–03.

28 Tarsy D, Sweadner KJ, Song PC. Case records of the Massachusetts General Hospital. Case 17-2010 - a 29-year-old woman with flexion of the left hand and foot and difficulty speaking. *N Engl J Med* 2010; **362:** 2213–19.

29 Roubergue A, Roze E, Vuillaumier-Barrot S, et al. The multiple faces of the ATP1A3-related dystonic movement disorder. *Mov Disord* 2013; **28:** 1457–59.

30 Brashear A, Mink JW, Hill DF, et al. *ATP1A3* mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. *Dev Med Child Neurol* 2012; **54:** 1065–67.

31 Heinzen EL, Swoboda KJ, Hitomi Y, et al, and the European Alternating Hemiplegia of Childhood (AHC) Genetics Consortium, and the Biobanca e Registro Clinico per l'Emiplegia Alternante (I.B.AHC) Consortium, and the European Network for Research on Alternating Hemiplegia (ENRAH) for Small and Medium-sized Enterpriese (SMEs) Consortium. De novo mutations in *ATP1A3* cause alternating hemiplegia of childhood. *Nat Genet* 2012; **44:** 1030–34.

32 Rosewich H, Thiele H, Ohlenbusch A, et al. Heterozygous de-novo mutations in *ATP1A3* in patients with alternating hemiplegia of childhood: a whole-exome sequencing gene-identification study. *Lancet Neurol* 2012; **11:** 764–73.

33 Ishii A, Saito Y, Mitsui J, et al. Identification of *ATP1A3* mutations by exome sequencing as the cause of alternating hemiplegia of childhood in Japanese patients. *PLoS One* 2013; **8:** e56120.

34 Hoei-Hansen CE, Dali CI, Lyngbye TJ, Duno M, Uldall P. Alternating hemiplegia of childhood in Denmark: clinical manifestations and *ATP1A3* mutation status. *Eur J Paediatr Neurol* 2014; **18:** 50–54.

35 Kamphuis DJ, Koelman H, Lees AJ, Tijssen MA. Sporadic rapid-onset dystonia-parkinsonism presenting as Parkinson's disease. *Mov Disord* 2006; **21:** 118–19.

36 Brashear A, Hill DF, Snively B, Sweadner KJ, Ozelius L. Denovo and recurrent mutations in *ATP1A3* are common in rapid-onset dystonia-parkinsonism. *Neurology* 2010; **74** (suppl 2): A204.

37 Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS Genet* 2013; **9:** e1003709.

38 Brashear A, Farlow MR, Butler IJ, Kasarskis EJ, Dobyns WB. Variable phenotype of rapid-onset dystonia-parkinsonism. *Mov Disord* 1996; **11:** 151–56.

39 Brashear A, Butler IJ, Ozelius LJ, et al. Rapid-onset dystonia-parkinsonism: a report of clinical, biochemical, and genetic studies in two families. *Adv Neurol* 1998; **78:** 335–39.

40 Brashear A, Butler IJ, Hyland K, Farlow MR, Dobyns WB. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. *Ann Neurol* 1998; **43:** 521–26.

41 Brashear A, Cook JF, Hill DF, et al. Psychiatric disorders in rapid-onset dystonia-parkinsonism. *Neurology* 2012; **79:** 1168–73.

42 Bourgeois M, Aicardi J, Goutières F. Alternating hemiplegia of childhood. *J Pediatr* 1993; **122:** 673–79.

43 Neville BG, Ninan M. The treatment and management of alternating hemiplegia of childhood. *Dev Med Child Neurol* 2007; **49:** 777–80.

44 Sweney MT, Silver K, Gerard-Blanluet M, et al. Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome. *Pediatrics* 2009; **123:** e534–41.

45 Silver K, Andermann F. Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment. *Neurology* 1993; **43:** 36–41.

46 Casaer P. Flunarizine in alternating hemiplegia in childhood. An international study in 12 children. *Neuropediatrics* 1987; **18:** 191–95.

47 Casaer P, Azou M. Flunarizine in alternating hemiplegia in childhood. *Lancet* 1984; **2:** 579.

48 Sasaki M, Sakuragawa N, Osawa M. Long-term effect of flunarizine on patients with alternating hemiplegia of childhood in Japan. *Brain Dev* 2001; **23:** 303–05.

49 Kanavakis E, Xaidara A, Papathanasiou-Klontza D, Papadimitriou A, Velentza S, Youroukos S. Alternating hemiplegia of childhood: a syndrome inherited with an autosomal dominant trait. *Dev Med Child Neurol* 2003; **45:** 833–36.

50 Bassi MT, Bresolin N, Tonelli A, et al. A novel mutation in the *ATP1A2* gene causes alternating hemiplegia of childhood. *J Med Genet* 2004; **41:** 621–28.

51 Swoboda KJ, Kanavakis E, Xaidara A, et al. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel *ATP1A2* mutation. *Ann Neurol* 2004; **55:** 884–87.

52 Andermann E, Andermann F, Silver K, Levin S, Arnold D. Benign familial nocturnal alternating hemiplegia of childhood. *Neurology* 1994; **44:** 1812–14.

53 Wagener-Schimmel LJ, Nicolai J. Child neurology: benign nocturnal alternating hemiplegia of childhood. *Neurology* 2012; **79:** e161–63.

54 Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: clinical manifestations and long-term outcome. *Pediatr Neurol* 2000; **23:** 134–41.

55 Saito Y, Sakuragawa N, Sasaki M, Sugai K, Hashimoto T. A case of alternating hemiplegia of childhood with cerebellar atrophy. *Pediatr Neurol* 1998; **19:** 65–68.

56 Saito Y, Inui T, Sakakibara T, Sugai K, Sakuma H, Sasaki M. Evolution of hemiplegic attacks and epileptic seizures in alternating hemiplegia of childhood. *Epilepsy Res* 2010; **90:** 248–58.

57 Dangond F, Garada B, Murawski BJ, Rey-Casserly C, Holman BL, Mikati MA. Focal brain dysfunction in a 41-year old man with familial alternating hemiplegia. *Eur Arch Psychiatry Clin Neurosci* 1997; **247:** 35–41.

58 Mikati M. Alternating hemiplegia of childhood. *Pediatr Neurol* 1999; **21:** 764.

59 Panagiotakaki E, Gobbi G, Neville B, et al, and the ENRAH Consortium. Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults. *Brain* 2010; **133:** 3598–610.

60 Verret S, Steele JC. Alternating hemiplegia in childhood: a report of eight patients with complicated migraine beginning in infancy. *Pediatrics* 1971; **47:** 675–80.

61 Krägeloh I, Aicardi J. Alternating hemiplegia in infants: report of five cases. *Dev Med Child Neurol* 1980; **22:** 784–91.

62 Mikati MA, Maguire H, Barlow CF, et al. A syndrome of autosomal dominant alternating hemiplegia: clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations. *Neurology* 1992; **42:** 2251–57.

63 Sasaki M, Ishii A, Saito Y, et al. Genotype-phenotype correlations in alternating hemiplegia of childhood. *Neurology* 2014; **82:** 482–90.

64 Di Michele M, Goubau C, Waelkens E, et al. Functional studies and proteomics in platelets and fibroblasts reveal a lysosomal defect with increased cathepsin-dependent apoptosis in ATP1A3 defective alternating hemiplegia of childhood. *J Proteomics* 2013; **86:** 53–69.

65 Post RL, Hegyvary C, Kume S. Activation by adenosine triphosphate in the phosphorylation kinetics of sodium and potassium ion transport adenosine triphosphatase. *J Biol Chem* 1972; **247:** 6530–40.

66 Toustrup-Jensen MS, Einholm AP, Schack VR, et al. Relationship between intracellular Na^+ concentration and reduced Na^+ affinity in Na^+,K^+-ATPase mutants causing neurological disease. *J Biol Chem* 2014; **289:** 3186–97.

67 Koenderink JB, Geibel S, Grabsch E, De Pont JJ, Bamberg E, Friedrich T. Electrophysiological analysis of the mutated Na,K-ATPase cation binding pocket. *J Biol Chem* 2003; **278:** 51213–22.

68 Poulsen H, Khandelia H, Morth JP, et al. Neurological disease mutations compromise a C-terminal ion pathway in the Na(+)/K(+)-ATPase. *Nature* 2010; **467:** 99–102.

69 Toustrup-Jensen M, Vilsen B. Importance of Glu(282) in transmembrane segment M3 of the Na(+),K(+)-ATPase for control of cation interaction and conformational changes. *J Biol Chem* 2002; **277:** 38607–17.

70 Rodacker V, Toustrup-Jensen M, Vilsen B. Mutations Phe785Leu and Thr618Met in Na^+,K^+-ATPase, associated with familial rapid-onset dystonia parkinsonism, interfere with Na^+ interaction by distinct mechanisms. *J Biol Chem* 2006; **281:** 18539–48.

71 Einholm AP, Toustrup-Jensen MS, Holm R, Andersen JP, Vilsen B. The rapid-onset dystonia parkinsonism mutation D923N of the Na^+, K^+-ATPase alpha3 isoform disrupts Na^+ interaction at the third Na^+ site. *J Biol Chem* 2010; **285:** 26245–54.

72 Ogawa H, Shinoda T, Cornelius F, Toyoshima C. Crystal structure of the sodium-potassium pump (Na^+,K^+-ATPase) with bound potassium and ouabain. *Proc Natl Acad Sci USA* 2009; **106:** 13742–47.

73 Kirshenbaum GS, Dawson N, Mullins JGL, et al. Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na^+,K^+-ATPase α3 missense mutant mice. *PLoS One* 2013; **8:** e60141.

74 Kaneko M, Desai BS, Cook B. Ionic leakage underlies a gain-of-function effect of dominant disease mutations affecting diverse P-type ATPases. *Nat Genet* 2014; **46:** 144–51.

75 Clapcote SJ, Duffy S, Xie G, et al. Mutation I810N in the α3 isoform of Na+,K+-ATPase causes impairments in the sodium pump and hyperexcitability in the CNS. *Proc Natl Acad Sci USA* 2009; **106:** 14085–90.

76 Moseley AE, Williams MT, Schaefer TL, et al. Deficiency in Na,K-ATPase alpha isoform genes alters spatial learning, motor activity, and anxiety in mice. *J Neurosci* 2007; **27:** 616–26.

77 DeAndrade MP, Yokoi F, van Groen T, Lingrel JB, Li Y. Characterization of *Atp1a3* mutant mice as a model of rapid-onset dystonia with parkinsonism. *Behav Brain Res* 2011; **216:** 659–65.

78 Ikeda K, Satake S, Onaka T, et al. Enhanced inhibitory neurotransmission in the cerebellar cortex of *Atp1a3*-deficient heterozygous mice. *J Physiol* 2013; **591:** 3433–49.

79 Ashmore LJ, Hrizo SL, Paul SM, Van Voorhies WA, Beitel GJ, Palladino MJ. Novel mutations affecting the Na, K ATPase alpha model complex neurological diseases and implicate the sodium pump in increased longevity. *Hum Genet* 2009; **126:** 431–47.

80 Doğanli C, Beck HC, Ribera AB, Oxvig C, Lykke-Hartmann K. α3Na+/K+-ATPase deficiency causes brain ventricle dilation and abrupt embryonic motility in zebrafish. *J Biol Chem* 2013; **288:** 8862–74.

81 Kirshenbaum GS, Clapcote SJ, Duffy S, et al. Mania-like behavior induced by genetic dysfunction of the neuron-specific Na^+,K^+-ATPase α3 sodium pump. *Proc Natl Acad Sci USA* 2011; **108:** 18144–49.

82 Kirshenbaum GS, Saltzman K, Rose B, Petersen J, Vilsen B, Roder JC. Decreased neuronal Na^+, K^+-ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. *Genes Brain Behav* 2011; **10:** 542–50.

83 Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na^+-K^+-ATPase alterations in ouabain and adducin-dependent hypertension. *Am J Physiol Regul Integr Comp Physiol* 2006; **290:** R529–35.

84 Pizoli CE, Jinnah HA, Billingsley ML, Hess EJ. Abnormal cerebellar signaling induces dystonia in mice. *J Neurosci* 2002; **22:** 7825–33.

85 Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid-onset dystonia-parkinsonism. *Nat Neurosci* 2011; **14:** 357–65.

86 Sweadner KJ. Isozymes of the Na^+/K^+-ATPase. *Biochim Biophys Acta* 1989; **988:** 185–220.

87 Rajarao SJ, Canfield VA, Mohideen MA, et al. The repertoire of Na,K-ATPase alpha and beta subunit genes expressed in the zebrafish, *Danio rerio*. *Genome Res* 2001; **11:** 1211–20.

88 Lebovitz RM, Takeyasu K, Fambrough DM. Molecular characterization and expression of the (Na^++K^+)-ATPase alpha-subunit in *Drosophila melanogaster*. *EMBO J* 1989; **8:** 193–202.

89 Palladino MJ, Bower JE, Kreber R, Ganetzky B. Neural dysfunction and neurodegeneration in Drosophila Na^+/K^+ ATPase alpha subunit mutants. *J Neurosci* 2003; **23:** 1276–86.

委託業務成果報告書への標記について

委託業務に係る成果報告書の表紙裏に、次の標記を行うものとする。

本報告書は、平成２６年度厚生労働科学研究委託事業による委託業務として、福岡大学が実施した平成26年度「Dravet（ドラベ）症候群患者由来iPS細胞を用いた認可医薬品スクリーニングによる革新的な医薬品開発のシーズ探索研究の成果を取りまとめたものです。